scholarly journals PROBABILITY ESTIMATION ON THE RISK OF MORTALITY OF PATIENTS WITH END-STAGE RENAL DISEASE

2016 ◽  
Vol 8 (2) ◽  
pp. 1 ◽  
Author(s):  
Jackie D. Urrutia ◽  
Jaya C. De Guzman ◽  
Aaron Vito M. Baygan ◽  
Edcon B. Baccay ◽  
Lincoln A. Bautista
Keyword(s):  
Cardiovascular Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Esrd Patient ◽  
Health Condition ◽  
The Philippines ◽  
Pulmonary Congestion ◽  
Risk Of Mortality ◽  
Stage Renal Disease ◽  
End Stage

<p class="lead">The kidneys perform life-maintaining functions like monitoring and regulating body fluids. These excrete excess fluids from the body and retain the substances necessary for the body’s continuing function. If the kidneys malfunction, it may cause some kidney complications that could lead to End-Stage Renal Disease (ESRD) or worst, it may lead to death. End-Stage Renal Disease (ESRD) or 5<sup>th</sup> stage chronic kidney failure is a growing health condition problem that continues to rise in the Philippines. Kidney Diseases especially End Stage Renal Diseases is the 7<sup>th</sup> leading cause of death in the country. Using Logistic Regression analysis, this study analyzed the record data such as the age, gender and the complications of 247 patients with Pulmonary Congestion and/or Cardiovascular disease diagnosed with ESRD at M. V. Makabali Memorial Hospital from the year 2008-2013. The present study was undertaken to identify the risk factors which causes to increase the death probability of an ESRD patient. The research concluded that pulmonary congestion and cardiovascular disease are significant factors that increase the patients’ probability to encounter death. Moreover, an ESRD patient with cardiovascular disease has a higher chance to encounter death with a probability of 68.52% than an ESRD patient with pulmonary congestions with a probability of 57.79%. The results also revealed that if a patient suffered from both complications, he/she has a higher risk of mortality with a probability of 98.6%. ESRD may not be curable but with the proper management of health condition and maintaining a healthy lifestyle, it can be prevented and possibly could lessen the risk of death.</p>

scholarly journals Association between Soluble Urokinase-Type Plasminogen Activator Receptor Levels and Chronic Kidney Disease: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Tiankui Shuai ◽  
Peijing Yan ◽  
Huaiyu Xiong ◽  
Qiangru Huang ◽  
Lei Zhu ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Risk Of Mortality ◽  
Stage Renal Disease ◽  
End Stage

Background. Chronic kidney disease (CKD) has become a global public health problem with a high prevalence and mortality. There is no sensitive and effective markers for chronic kidney disease. Previous studies proposed suPAR as an early predict biomarker for chronic kidney disease, but the results are controversial. Therefore, the purpose of the current meta-analysis is to evaluate the association between suPAR and CKD. Methods. We searched the PubMed, Embase, Cochrane Library databases, and Web of Science before May 1, 2019. The search was based on the key words including suPAR and CKD. Data are extracted independently according to standard format, and quality analysis is performed. We extracted the concentration of suPAR and hazard rate (HR) values of mortality, cardiovascular disease, and end-stage renal disease. Results. There were 14 studies fulfilling the criteria. The concentration of suPAR was higher in patients with CKD than that in the control group (P<0.001; SMD: −2.17; 95% CI: −2.71, −1.63; I2 = 67.4%). SuPAR had a higher risk of mortality (P=0.001; HR: 1.72; 95% CI: 1.24, 2.39; I2 = 68.0%). The higher suPAR level increased the risk of cardiovascular disease (P<0.001; HR: 3.06; 95% CI: 2.21, 4.22; I2 = 0.0%) and the risk of end-stage renal disease (P<0.001; HR: 1.40; 95% CI: 1.22, 1.60; I2 = 0.0%). Conclusions. Monitoring suPAR concentrations may be used for early diagnosis and prognosis for patients with CKD, and the higher suPAR increased the risk of mortality, cardiovascular events, and end-stage renal disease.

scholarly journals Obesity, End-stage Renal Disease, and Survival in an Elderly Cohort With Cardiovascular Disease

Obesity ◽  
2009 ◽  
Vol 17 (12) ◽  
pp. 2216-2222 ◽  
Author(s):  
Janice P. Lea ◽  
Daryl O. Crenshaw ◽  
Stephen J. Onufrak ◽  
Britt B. Newsome ◽  
William M. McClellan
Keyword(s):  
Cardiovascular Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elderly Cohort ◽  
Stage Renal Disease ◽  
End Stage

Cardiovascular Disease as a Late Complication of End-Stage Renal Disease in Children

2005 ◽  
Vol 25 (3_suppl) ◽  
pp. 123-126 ◽  
Author(s):  
Jaap Groothoff ◽  
Mariken Gruppen ◽  
Eric De Groot ◽  
Martin Offringa
Keyword(s):  
Cardiovascular Disease ◽  
Aortic Valve ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Arterial Wall ◽  
Aortic Valve Calcification ◽  
Cross Sectional ◽  
Valve Calcification ◽  
Stage Renal Disease ◽  
End Stage

♦ Objective To analyze the late cardiovascular outcome of end-stage renal disease (ESRD) in children. ♦ Design A nation-wide long-term follow-up study. Determinants of outcomes and causes of death were retrospectively assessed. Patients underwent assessment of overall health state, B- and M-mode ultrasound of the carotid arteries, and echocardiography for cross-sectional analysis. ♦ Results We analyzed the medical course of all 249 adult Dutch patients with ESRD onset between 1972 and 1992 at age 0 – 14 years, and who were born before 1979. Of the 187 living patients, 140 participated in the cross-sectional part of the study. The standardized mortality rate was 31.0. Overall 5-, 10-, and 20-year survival after ESRD onset was 87%, 82%, and 78%, respectively. Cardiovascular disease accounted for most deaths (41%). In the whole group, left ventricular hypertrophy (LVH), aortic valve calcification, and arterial wall stiffening were highly prevalent. LVH was associated with hypertension at time of assessment. Aortic valve calcification was strongly associated with a long total duration of peritoneal dialysis (β = 0.33, p < 0.001). Arterial wall pathology was not associated with current treatment modality. ♦ Conclusions As in adults, cardiovascular disease is the most important cause of death in children with ESRD. Stricter reduction of volume overload, prevention of high serum calcium–phosphate product, and more vigorous treatment of hypertension are important targets to improve cardiovascular survival in children with ESRD.

scholarly journals Indoxyl Sulfate-Mediated Metabolic Alteration of Transcriptome Signatures in Monocytes of Patients with End-Stage Renal Disease (ESRD)

Toxins ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 621
Author(s):  
Hee Young Kim ◽  
Su Jeong Lee ◽  
Yuri Hwang ◽  
Ga Hye Lee ◽  
Chae Eun Yoon ◽  
...  
Keyword(s):  
Renal Disease ◽  
Immune Cells ◽  
End Stage Renal Disease ◽  
Metabolic Pathways ◽  
Esrd Patient ◽  
Indoxyl Sulfate ◽  
Uremic Toxin ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

End-stage renal disease (ESRD) is the final stage of chronic kidney disease, which is increasingly prevalent worldwide and is associated with the progression of cardiovascular disease (CVD). Indoxyl sulfate (IS), a major uremic toxin, plays a key role in the pathology of CVD via adverse effects in endothelial and immune cells. Thus, there is a need for a transcriptomic overview of IS responsive genes in immune cells of ESRD patients. Here, we investigated IS-mediated alterations in gene expression in monocytes from ESRD patients. Transcriptomic analysis of ESRD patient-derived monocytes and IS-stimulated monocytes from healthy controls was performed, followed by analysis of differentially expressed genes (DEGs) and gene ontology (GO). We found that 148 upregulated and 139 downregulated genes were shared between ESRD patient-derived and IS-stimulated monocytes. Interaction network analysis using STRING and ClueGo suggests that mainly metabolic pathways, such as the pentose phosphate pathway, are modified by IS in ESRD patient-derived monocytes. These findings were confirmed in IS-stimulated monocytes by the increased mRNA expression of genes including G6PD, PGD, and TALDO1. Our data suggest that IS causes alteration of metabolic pathways in monocytes of ESRD patients and, thus, these altered genes may be therapeutic targets.

Assessing Plasma Total Homocysteine in Patients with End-Stage Renal Disease

2007 ◽  
Vol 27 (5) ◽  
pp. 476-488 ◽  
Author(s):  
Bradley L. Urquhart ◽  
Andrew A. House
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elevated Plasma ◽  
Plasma Thcy ◽  
Total Homocysteine ◽  
Stage Renal Disease ◽  
End Stage ◽  
Plasma Total Homocysteine

Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease; however, in light of several recent randomized trials, the issue of causality has been cast into doubt. Patients with end-stage renal disease are particularly interesting as they consistently have elevated tHcy and their leading causes of morbidity and mortality are related to cardiovascular disease. In the present article, we review the early evidence for the homocysteine theory of atherosclerosis, homocysteine metabolism, mechanisms of toxicity, and pertinent available clinical investigations. Where appropriate, the sparse evidence of homocysteine in peritoneal dialysis is reviewed. We conclude by addressing the difficulties associated with lowering plasma tHcy in patients with end-stage renal disease and suggest some novel methods for lowering tHcy in this resistant population. Finally, to address the issue of causality, we recommend that clinicians and scientists await the results of the FAVORIT trial before abandoning homocysteine as a modifiable risk factor for cardiovascular disease, as this study has recruited patients from a population with consistently elevated plasma tHcy who are known to respond to vitamin therapy.

Sign in / Sign up

Export Citation Format

Share Document